Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2009

Chinese Authorities Clear China Medical’s Leukemia Diagnostic Kit

  • China Medical Technologies received Chinese regulatory approval for its leukemia BCR/ABL fusion gene detection FISH probe. The molecular diagnostic test kit is used to detect the Philadelphia translocation genetic defect associated with chronic myeloid leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia.

    China Medical develops, manufactures, and markets advanced IVD products using FISH, enhanced chemiluminescence, and surface plasmon resonance (SPR) technologies. In October Chinese regulatory authorities approved the company’s SPR-based analysis system, for which an HPV-DNA biosensor chip is available.

    The company already offers a range of FISH probes for diseases including breast cancer, bladder cancer, and cervical cancer. Additional FISH probes are also in clinical development or under regulatory review in China.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »